drugset
drugset / Trial / NCT04438850

COVidIVERmectin: Ivermectin for Treatment of Covid-19

NCT04438850 ↗

Phase 2 Terminated 93 enrolled IRCCS Sacro Cuore Don Calabria di Negrar Istituto Di Ricerche Farmacologiche Mario Negri · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of ivermectin for the treatment of initial infection with SARS-CoV2 infection. Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I\_600) + placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days (I\_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres. In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.

Timeline

Start
2020-07-31
Primary completion
2021-06-08
Completion
2021-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 600 ug/kg Oral
Subject Ivermectin Small molecule 1200 ug/kg Oral

Indications

COVID-19